Table 2.
List of various potential synthetic HIF-1α inhibitors based on their mode of action in different cancers.
| Serial No. |
Name | Structure | Mode of Action | Effective against Cancer Type | Clinical Trial | Reference |
|---|---|---|---|---|---|---|
| 1 | YC-1 |
|
HIF-1α synthesis blocker | Hepatoma, gastric cancer, lung cancer, prostate cancer, pancreatic cancer, Human Bladder Transitional Carcinoma |
----- | [127,133,195,196,197,198,199,200,201,202] |
| 2 | PX-478 |
|
Colon carcinoma, Lung Adenocarcinoma, pancreatic ductal adenocarcinoma | Phase I | [127,133,203,204] | |
| 3 | DJ12 |
|
HIF-1α activity blocker | Breast cancer, Melanoma, Renal cancer | ----- | [127,133,205] |
| 4 | Bortezomib |
|
Human hepatoma, multiple myeloma, human embryonic kidney and human multiple myeloma | Approved | [127,133,206,207,208] | |
| 5 | Amphotericin B (AmB) |
|
Hepatocellular carcinoma, | Approved | [127,133,209] | |
| 6 | Polyamides |
|
Adenocarcinoma | ----- | [127,133,210] | |
| 7 | ENMD-1198 (Analog of 2ME2) |
|
HIF-1α degradation enhancer | Prostate cancer, breast cancer, human hepatocellular carcinoma | ----- | [127,133,211,212,213] |
| 8 | Zebularine |
|
Oral squamous cell carcinoma | ----- | [127,133,214] | |
| 9 | 17-AAG (Analog of Geldanamycin) |
|
Prostate cancer, renal cell carcinoma, papillary thyroid carcinoma | Phase III | [127,133,215,216] | |
| 10 | Flavopiridol |
|
Leukemia, human glioma, neuroblastoma | Phase II | [127,133,217,218,219,220,221,222] |